PayPal Holdings, Inc. vs Summit Therapeutics Inc — how do they compare? PayPal Holdings, Inc. trades at $55.47 (market cap $49.27B), while Summit Therapeutics Inc trades at $14.78 (market cap $11.34B). The key difference: PayPal Holdings, Inc. is far larger — about 4.3× Summit Therapeutics Inc's market cap, and PayPal Holdings, Inc. pays a 1% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| PYPL | SMMT | |
|---|---|---|
Market Cap | $49.27B | $11.34B |
Sector | Financials | Health |
52-Week High | $78.22 | $29.32 |
52-Week Low | $39.08 | $13.05 |
Enterprise Value | $49.33B | $10.76B |
Dividend Yield | 1% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Trailing returns across standard periods
Latest headlines on both assets
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →